In addition, according to CIVIC database there are no FDA-approved or NCCN-compendium register treatments especially for patients that carry some of the LA reported variants such as R248Q variant for TP53, since this variant has been correlated with worse overall survival in BC patients in contrast to wild-type [41,42]. Here, TP53 is linked to breast cancer.